Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk c19early.org/s Zhu et al. Remdesivir for COVID-19 META ANALYSIS Favors remdesivir Favors control
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531 (Preprint) (meta analysis)
Zhu et al., Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind,.., medRxiv, doi:10.1101/2020.06.22.20136531
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).
Currently there are 48 remdesivir studies and meta analysis shows:
OutcomeImprovement
Mortality14% lower [5‑21%]
Ventilation10% higher [-22‑54%]
ICU admission33% higher [10‑62%]
Hospitalization3% higher [-20‑32%]
risk of death, 36.0% lower, RR 0.64, p = 0.02.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhu et al., 29 Jun 2020, preprint, 11 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials Yun Zhu1, M.D., Zhaowei Teng1,2,3, Ph.D., Lirong Yang3, Ph.D., Shuanglan Xu3, M.D., Jie Liu3, M.D., Yirong Teng1, M.D., Qinggang Hao2, M.D., Dake Zhao2, Ph.D., Xiaolan Li4, M.D., Sheng Lu2, M.D., Yong Zeng1, M.D. 1 The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, China 2 The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China 3 Graduate School of Kunming Medical University, Kunming, China 4 The Second Affiliated Hospital of Kunming Medical University, Kunming, China All authors contributed equally to this paper. Correspondence to: Yun Zhu The Sixth Affiliated Hospital of Kunming Medical University 21 Nieer Road, Yuxi 653100, Yunnan, China Tel.: (86) 13887731212 e-mail: zhuyun8377@163.com NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract BACKGROUND Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has been identified as a candidate for COVID-19 treatment. However, the therapeutic effect of remdesivir is controversial. METHODS We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical efficacy of remdesivir. The main outcomes were discharge rate, mortality, and adverse events. This study is registered at INPLASY (INPLASY202060046). RESULTS Data of 1075 subjects showed that remdesivir significantly increased the discharge rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 [95% confidence interval [CI], 1.05–1.34], I2 = 0.0%, P = 0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44–0.92], I2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects showed that remdesivir significantly decreased the occurrence of serious adverse events (RR 0.77 [95% CI, 0.63–0.94], I2 = 0.0%, P = 0.716). CONCLUSION Remdesivir is efficacious and safe for the treatment of COVID-19. TRIAL REGISTRATION NUMBER 2 medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . This study is registered at the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202060046). 3 medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020...
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit